Absher Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-1,800
Closed -$244K 78
2021
Q2
$244K Buy
+1,800
New +$237K 0.04% 67
2021
Q1
Sell
-1,800
Closed -$253K 74
2020
Q4
$253K Hold
1,800
0.05% 63
2020
Q3
$201K Hold
1,800
0.05% 66
2020
Q2
$202K Buy
+1,800
New +$177K 0.05% 68

Other funds holding XBI

Absher Wealth Management's XBI Position: Q3 2021 in Review

Absher Wealth Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2021, closing a stake of 1,800 shares — an estimated $244K sold.

Absher Wealth Management first reported a position in XBI in Q2 2020 and held it in 4 quarters. The position peaked at $253K in Q4 2020. 635 funds tracked by Wall St. Rank hold XBI as of Q3 2021.

  • Absher Wealth Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2021 after selling out during the quarter.
  • Absher Wealth Management sold 1,800 State Street SPDR S&P Biotech ETF shares in Q3 2021, an estimated $244K.
  • Absher Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2020 and held it in 4 quarters.
  • Absher Wealth Management's State Street SPDR S&P Biotech ETF position peaked at $253K in Q4 2020.
  • 635 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2021.

Based on Absher Wealth Management's 13F filing for Q3 2021, filed 4 Nov 2021.